As infectious diseases become less treatable with the rise of antibiotic resistance, it is becoming increasingly imperative to create new antibiotics to fight the resistance, especially ones with a novel method of bacterial inhibition. Tuberculosis is arguably the most pressing infectious disease that requires new antibiotics to fight its resistance. An FDA approved drug currently used for fighting tuberculosis is Linezolid, also known as Zyvox, which contains an oxazolidinone ring. The purpose of this research is to synthesize an oxazolidinone derivative, which can be tested for efficacy against resistant bacteria and bioavailability. This derivative will contain a primary amine, which will aid in increasing hydrogen bonding within the active site and water solubility, thus increasing bioavailability. The synthesis of this compound requires protection and deprotection of the primary amine using BOC groups and is a total of eight steps to the final product. This amine-containing derivative will also be used to synthesize further oxazolidinone derivatives.

Novel synthesis of a new oxazolidinone antimicrobial agent

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.